B
Bull
Bull · 25%OACC
$12.28
Scenario price
$10.740
0.000 (0.00%)At close
Loading chart…
- High
- 10.800
- Open
- 10.800
- VWAP
- 10.76
- Vol
- 36.03K
- Mkt Cap
- —
- Low
- 10.740
- Amount
- 387.72K
- EV/EBITDA, TTM
- 0.00
Oaktree Acquisition III Life Sciences Corp is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company has not commenced any operations. The Company has not generated any revenues.
AI analysis of Oaktree Acquisition III Life Sciences Corp (OACC)
holdOaktree Acquisition Corp. III is currently not a strong buy due to its recent performance and financial metrics. The current price is $10.74, with an RSI of 43.35 indicating a neutral momentum. Although the forward P/E is 0, suggesting potential undervaluation, the company has shown a negative net income of -48095.00 USD in Q3 2024, which raises concerns about profitability. The stock has only a 1.18% year-to-date change, indicating limited growth. The main risk is the current ratio of 0.87, which suggests potential liquidity issues.
Valuation Metrics
The current forward P/E ratio for Oaktree Acquisition III Life Sciences Corp (OACC) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for OACC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding OACC
OACC FAQ — answered by Alphio AI
Oaktree Acquisition III Life Sciences Corp is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company has not commenced any operations. The Company has not generated any revenues. It operates in the Financials sector.
Oaktree Acquisition Corp. III is currently not a strong buy due to its recent performance and financial metrics. The current price is $10.74, with an RSI of 43.35 indicating a neutral momentum. Although the forward P/E is 0, suggesting potential undervaluation, the company has shown a negative net income of -48095.00 USD in Q3 2024, which raises concerns about profitability. The stock has only a 1.18% year-to-date change, indicating limited growth. The main risk is the current ratio of 0.87, which suggests potential liquidity issues.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.